Literature DB >> 16175074

Prevalence of underlying adenocarcinoma in women with atypical endometrial hyperplasia.

Jamie Shutter1, Thomas C Wright.   

Abstract

There is controversy regarding the prevalence of underlying endometrial adenocarcinoma among women with a diagnosis of atypical endometrial hyperplasia. This study further defines that risk. At our institution atypical endometrial proliferations non-diagnostic for invasive adenocarcinoma are diagnosed as either atypical endometrial hyperplasia (ATHY) or as an "atypical proliferative lesion of the endometrium, suggestive but not diagnostic of atypical endometrial hyperplasia" (APL). Between 1996 and 2003, these diagnoses were made on either endometrial biopsy or endometrial curettings in 60 women who subsequently received a hysterectomy. Endometrial adenocarcinoma was identified in 48% (29/60) of the hysterectomy specimens. Age and sampling method had no significant impact on the prevalence of adenocarcinoma. Adenocarcinoma was no more likely to be subsequently identified when a woman had a preoperative diagnosis of ATHY (24 of 52, 46%) compared to APL (5 of 8, 63%). In some women with a diagnosis of ATHY a comment was made in the report that "carcinoma cannot be ruled out". These cases had a significantly higher prevalence of underlying adenocarcinoma (16 of 25, 64%) compared to cases of ATHY in which such a comment was not made (8 of 27, 30%) (p = 0.025). In conclusion, there is a high prevalence of underlying endometrial adenocarcinoma among women undergoing hysterectomy for any of atypical endometrial proliferation.

Entities:  

Mesh:

Year:  2005        PMID: 16175074     DOI: 10.1097/01.pgp.0000164598.26969.c3

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  12 in total

1.  Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.

Authors:  Kristen Upson; Kimberly H Allison; Susan D Reed; Carolyn D Jordan; Katherine M Newton; Elizabeth M Swisher; Jennifer A Doherty; Rochelle L Garcia
Journal:  Am J Obstet Gynecol       Date:  2012-05-16       Impact factor: 8.661

2.  Endometrial cancer.

Authors:  Kimberly K Leslie; Kristina W Thiel; Michael J Goodheart; Koen De Geest; Yichen Jia; Shujie Yang
Journal:  Obstet Gynecol Clin North Am       Date:  2012-06       Impact factor: 2.844

3.  Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy.

Authors:  Susan D Reed; Katherine M Newton; Rochelle L Garcia; Kimberly H Allison; Lynda F Voigt; C Diana Jordan; Meira Epplein; Elizabeth Swisher; Kristen Upson; Kelly J Ehrlich; Noel S Weiss
Journal:  Obstet Gynecol       Date:  2010-08       Impact factor: 7.661

4.  Uterine epithelial cell proliferation and endometrial hyperplasia: evidence from a mouse model.

Authors:  Yang Gao; Shu Li; Qinglei Li
Journal:  Mol Hum Reprod       Date:  2014-04-25       Impact factor: 4.025

5.  Significance of concurrent endometrial cancer in women with a preoperative diagnosis of atypical endometrial hyperplasia.

Authors:  Kurt Christopher Giede; Tin-Wing Yen; Rajni Chibbar; Roger A Pierson
Journal:  J Obstet Gynaecol Can       Date:  2008-10

6.  Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia.

Authors:  James V Lacey; Mark E Sherman; Brenda B Rush; Brigitte M Ronnett; Olga B Ioffe; Máire A Duggan; Andrew G Glass; Douglas A Richesson; Nilanjan Chatterjee; Bryan Langholz
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

Review 7.  The endometrial hyperplasias revisited.

Authors:  Efthimios Sivridis; Alexandra Giatromanolaki
Journal:  Virchows Arch       Date:  2008-08-23       Impact factor: 4.064

Review 8.  Transforming growth factor β signaling in uterine development and function.

Authors:  Qinglei Li
Journal:  J Anim Sci Biotechnol       Date:  2014-11-14

9.  Risk factor analysis of coexisting endometrial carcinoma in patients with endometrial hyperplasia: a retrospective observational study of Taiwanese Gynecologic Oncology Group.

Authors:  Yu-Li Chen; Kung-Liahng Wang; Min-Yu Chen; Mu-Hsien Yu; Chen-Hsuan Wu; Yu-Min Ke; Yi-Jen Chen; Yin-Yi Chang; Keng-Fu Hsu; Ming-Shyen Yen
Journal:  J Gynecol Oncol       Date:  2013-01-08       Impact factor: 4.401

10.  Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan.

Authors:  J V Lacey; O B Ioffe; B M Ronnett; B B Rush; D A Richesson; N Chatterjee; B Langholz; A G Glass; M E Sherman
Journal:  Br J Cancer       Date:  2007-11-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.